Abstract: Iodophore containinga) 20-71% by weight of PVP or poly-N-vinylcaprolactam,b) 20-71% by weight of dextrin of DE 2-40,c) 6-25% by weight of elemental iodine,d) 3-12.5% by weight of iodide ions,and process for its preparation are disclosed.

Abstract: This invention relates to clear aqueous solutions of hydrocortisone which are free of lower alcohols. When applied to the skin, either directly or by wipe, the solution is practically invisible and has a further advantage that the solution will not irritate or dry the skin or give the stinging sensation of an alcohol containing solution. Dissolution of hydrocortisone without alcohol is accomplished by using the anionic surfactant sodium dioctyl sulfosuccinate in mixtures of glycerin, propylene glycol and polyethylene glycol diluted to final volume with water.

Abstract: A pesticide preparation of aqueous suspension type which comprises:(a) a 1,1'-iminiodi(octamethylene)diguanidinium tris(alkyl-benzenesulfonate) as an active pesticide ingredient;(b) at least one dispersion stabilizer selected from among alcohols having a degree of ethoxylation of 0 to 4 and carrying an alkyl group or an alkenyl group having 8 to 18 carbon atoms and phospholipids;(c) at least one surfactant selected from among surfactants carrying an alkyl group or an alkenyl group having 6 to 20 carbon atoms; and(d) water.

Abstract: The cosmetic composition is disclosed by blending at least an antibacterial zeolite, having all or part of its ion exchangeable ions substituted by ammonium ions and antibacterial metal ions, and silicone.

Abstract: An aqueous composition comprising a lower aliphatic peracid, a corrosion inhibitor and a peroxide stabilizer and/or peracid stabilizer, is useful for disinfecting medical equipment, particularly metal components of such equipment. A process for obtaining such compositions is also provided and comprises mixing a first aqueous solution comprising a lower aliphatic peracid with a second aqueous solution comprising hydrogen peroxide, a corrosion inhibitor and a hydrogen peroxide stabilizer and/or a peracid stabilizer. The first and second aqueous solutions can form a two pack system for obtaining such compositions.

Abstract: A coating base for solid enteric pharmaceutical preparations having a dissolution pH ranging from 3.5 to 4.5 essentially consisting of hydroxypropylmethyl cellulose trimellitate obtained by substituting water-soluble hydroxypropylmethyl cellulose having 1.1 to 1.6 methoxy group per glucose ring thereof with 0.2 to 1.0 trimellitate group per glucose ring, or obtained by substituting water-soluble hydroxypropylmethyl cellulose having 1.7 to 2.1 methoxy groups per glucose ring thereof with 0.2 to 0.5 trimellitate group per glucose ring. The coating base can be dissolved at the upper portion of the small intestine without delay and a solid enteric pharmaceutical preparation provided with a coating film of the base can completely release the drug included therein before the preparation passes through the small intestine. Therefore, the base can ensure a high pharmacological action of the drug.

Abstract: Cosmetic composition, characterized in that it contains titanium dioxide nanopigments coated with at least aluminium derivatives in a cosmetically acceptable, fairly nonpolar medium having a conductivity of less than 100 .mu.Siemens and containing at least one fatty phase.

Abstract: The present invention is directed to a chemically stable pharmaceutical composition containing ibuprofen in combination with terfenadine, wherein the oxidation of terfenadine to terfenadone is prevented by the presence in the composition of an .alpha.-hydroxy carboxylic acid.

Abstract: There is disclosed a stable pharmaceutical solid composition comprising enalapril as the sodium salt, which is made by the steps of:i) mixing enalapril maleate with a carrier, an alkaline sodium compound, and waterii) drying the wet mass, and;iii) further processing the resultant dried mass into tablets.When the water is added in the aforesaid process, an acid-base reaction occurs which converts the enalapril maleate into the more stable enalapril sodium salt.

Abstract: This invention is to provide a cosmetic composition which comprises dl-.alpha.-tocopheryl 2-L-ascorbyl phosphate phosphate and/or a salt thereof in stabilized condition. The cosmetic composition comprises one or more members of the group consisting of a polyhydric alcohol derivative, urea, and a sub-critical micelle concentration of a nonionic surfactant as formulated with said dl-.alpha.-tocopheryl 2-L-ascorbyl phosphate or salt thereof.

Abstract: The invention concerns a kit for the preparation of an emulsion containing prostaglandin E.sub.1, a method of preparing the emulsion and a method of preparing the emulsion composition contained in the kit. The emulsion prepared using this kit is suitable for parenteral application.

Abstract: Invented are stabilized tablet formulations of substituted 3,5-diene steroidal compounds. Also invented are methods of preparing stabilized tablet formulations of substituted 3,5-diene steroidal compounds.

Abstract: Disclosed are reconstituted lyophilized formulations for the treatment of mammalian tumors comprising a thioxanthenone antitumor agent in combination with mannitol or sucrose as a stabilizer in a lactate buffer.

Abstract: The present invention relates to a microemulsion concentrate containing cyclosporin as an active ingredient, dimethylisosorbide as a cosurfactant, oil and a surfactant which is suitable for the formulation of a soft capsule for oral administration, said cyclosporin, dimethyl isosorbide, oil and surfactant being present in the ratio of 1:1-5:1-5:2-10, and preferably in the ratio of 1:2-4:2-5:2-4:7, by weight. Since dimethylisosorbide has substantially no membrane permeation property, the soft capsule preparation according to the present invention is outstandingly stable in comparison with the soft capsules containing ethanol, propylene glycol, transcutol, glycofurol, etc., as a cosurfactant in the prior art, and further provides an advantage in that the pharmaceutical effect, appearance and composition content of the soft capsule according to the present invention are not changed.

Abstract: The present invention relates to an aqueous pharmaceutical suspension for oral use, and a method of preparation, having antacid and antiulcer properties which contains a therapeutically effective amount of calcium carbonate in combination with magnesium carbonate and/or magnesium trisilicate and a carboxylic acid pH adjusting agent.

Abstract: A biocompatible microcapsule containing living cells encapsulated in a membrane is disclosed. The membrane is a complex formed by the cohesion of two polymer layers. An inner layer comprises a substrate biopolymer and an outer layer comprises a synthetic polyelectrolyte having an electrolytic charge opposite that of the substrate biopolymer. Droplets of a solution of substrate biopolymer containing a suspension of living cells can be added to a solution comprising the synthetic polyelectrolyte to form the encapsulates. The membrane is formed by the cohesion of the oppositely-charge polymer layers to form a complex of substrate biopolymer and synthetic polyelectrolyte. Preferably, the inner layer contains a cationic biopolymer, such as collagen modified to have a pKI of 9, or an anionic biopolymer such as esterified or modified hyaluronic acid.

Abstract: Provided is an anti-microbial composition containing an ester of formic acid, an oxidizer, performic acid and water. Also provided is a premix for making the anti-microbial composition having two parts. One part contains the ester of formic acid and a second part contains the oxidizer. Another method is provided for making the anti-microbial composition in which the ester of formic acid is combined with the oxidizer and water.

Abstract: Parenteral pharmaceutical formulations of human growth hormone, which are stabilized against aggregation, comprising biosynthetic human growth hormone, glycine, and mannitol. Methods of reducing aggregation of human growth hormone in parenteral formulations are also provided.

Abstract: A stabilized composition capable of releasing an active agent in contact with the skin, contains at least two precursors of this same active agent, capable of simultaneously releasing this active agent by at least two different specific enzymatic reactions in order to release a large amount of active agent at a faster rate than the sum of the rates of the first enzymatic reaction and of the second enzymatic reaction taken separately, the first precursor being chosen from active agent monosaccharide derivatives and active agent amides. The composition is useful for dermatological and/or cosmetic treatments applied topically.

Abstract: The present invention provides improved methods for manufacturing solutions including medical solutions. To this end, in an embodiment, a method for preparing a medical solution is provided comprising the steps of: placing a solution in a gas permeable container; and allowing carbon dioxide to permeate through the container until a desired pH is achieved.

Abstract: The present invention relates to a soft capsule composition containing a stable microemulsion concentrate which is more stable and suitable for the preparation of cyclosporin-containing soft capsules. More specifically, the present invention relates to a microemulsion concentrate containing cyclosporin as an active ingredient, dimethylisosorbide as a co-surfactant, one component or a mixture of two or more selected from the group consisting of an esterified compound of fatty acid and primary alcohol, medium chain fatty acid triglyceride and monoglyceride as an oil component, and a surfactant having HLB value of 10 to 17, such as Nikkol HCO-50 or Tween 20, which is suitable for formulation into soft capsules and to a soft capsule composition containing said microemulsion concentrate. In the microemulsion concentrate according to the present invention, cyclosporin, dimethylisosorbide, the oil component and the surfactant are present in the ratio of 1:11-5:1-5:3-6, preferably 1:3-4:1.

Abstract: A formulation consisting of an active ingredient (herbicide or pesticide) suspended in an organic medium containing, in addition to usual additives, a polymer and protic solvent and a process for the preparation of such formulation.

Abstract: An aqueous isothiazolone formulation useful for antiseptic or antifungal treatment of various synthetic polymeric emulsions, which comprises (a) a specific isothiazolone compound, (b) water or an aqueous solvent and (c) a specific nitrobromo or cyanobromo compound.

Abstract: The invention relates to an insecticidal composition which comprises at least one pyrethroid, at least one UV absorbing agent and at least one antioxidant from the group consisting of tocopherol derivatives and citric acid esters. This insecticidal composition can in particular be used as an emulsion or on a powdery carrier for the control of flying and crawling insects such as flies and cockroaches.

Abstract: Provided is an anti-microbial composition containing an ester of formic acid, an oxidizer, performic acid and water. Also provided is a premix for making the anti-microbial composition having two parts. One part contains the ester of formic acid and a second part contains the oxidizer. Another method is provided for making the anti-microbial composition in which the ester of formic acid is combined with the oxidizer and water. Also provided is a method for sterilizing devices by contacting the surface of the device with the anti-microbial composition containing the ester of formic acid, an oxidizer, performic acid and water.

Abstract: The present invention relates to improved specific binding assay methods, kits and devices utilizing chromatographically mobile specific binding reagents labelled with colloidal particles. Specific binding reagents labelled with colloidal particles such as gold and selenium may be subjected to rapid chromatographic solvent transport on chromatographic media by means of selected solvents and chromatographic transport facilitating agents. Further, impregnation of solid substrate materials with labile protein materials including colloidal particle and enzyme labelled reagents in the presence of meta-soluble proteins provides for the rapid resolubilization of such materials which have been dried onto such substrate materials.

Abstract: There is disclosed a stable pharmaceutical solid composition comprising enalapril as the sodium salt, which is made by the steps of:i) mixing enalapril maleate with a carrier, an alkaline sodium compound, and waterii) drying the wet mass, and;iii) further processing the resultant dried mass into tablets.When the water is added in the aforesaid process, an acid-base reaction occurs which converts the enalapril maleate into the more stable enalapril sodium salt.

Abstract: A safe, stabilized lyophilized preparation comprising parathyroid hormone (PTH) as an active ingredient and effective amounts of sugar and sodium chloride to provide a stable preparation of parathyroid hormone.

Abstract: A stable lyophilized composition of the antitumor alkylating agent thiotepa and a method of preparing such a composition via co-lyophilization of the active ingredient with a pharmaceutical acceptable alkalizing agent.

Abstract: The present invention relates to a cyclosporin-containing powder composition which comprises cyclosporin, a non-ionic hydrophilic surfactant and a porous carrier. In addition, the present invention relates to a method for preparing the cyclosporin-containing powder composition which comprises dissolving cyclosporin and a non-ionic hydrophilic surfactant in an organic solvent, adding a porous carrier to the resulting solution and then evaporating the organic solvent from the mixture. The powder composition of the present invention is stable and does not require a special manufacturing technique when it is formulated. In addition, since the powder composition of the present invention does not contain an organic solvent, the necessity of a special package is excluded. Furthermore, the composition of the present invention provides an improved bioavailability which results in decrease of a single dosage, and therefore, can contribute to the alleviation of the side effects associated with cyclosporin.

Abstract: An extended-release galenical form of Diltiazem or a pharmaceutically acceptable salt thereof, which comprises beads containing said Diltiazem or a pharmaceutically acceptable salt thereof as an active ingredient and a wetting agent, said beads being coated with a microporous membrane comprising at least a water-soluble or water-dispersible polymer or copolymer and a pharmaceutically acceptable adjuvant.

Abstract: The present application relates to novel compounds of the benzo-heterocycle family as well as to processes for their preparation and to the intermediate compounds obtained.

Abstract: A method for treating a patient suffering from any of osteoporosis, Paget's disease and hypercalcemia by intranasally administering to said patient by spray a calcitonin solution consisting of calcitonin dissolved in a 0.9% aqueous sodium chloride solution free of quaternary ammonium compounds and surfactants, the calcitonin being in a concentration of 100-5000 IU per ml. of composition.

Abstract: A method for preparing ibuprofen granulations which exhibit improved stability and resistance to the formation of low melting point eutectics is disclosed. The method includes forging an amalgamation of ibuprofen and an alkali metal in a physical matrix which is suitable for inclusion in a composition without destroying the amalgamation. The stabilized ibuprofen granulation can be combined with other active ingredients and/or excipients to form compositions which have extended shelf life and are resistant to the formation of low melting point eutectics.

Abstract: This invention provides pharmaceutical preparations containing highly concentrated tumor cytotoxic factor (TCF). The pharmaceutical preparations of the present invention contain highly concentrated TCF and a basic amino acid or their salts, or an organic or inorganic salt as a solubizer. The resultant compositions described in the present invention dissolve TCF at high concentrations of 10 mg/ml or over under about neutral and isotonic conditions. The resultant compositions are stable and are suitable for injection preparations.

Abstract: The disclosed invention includes a base coated acid formulation which is highly compressible. The disclosed invention also relates to formulations including both an effervescent couple and an acid sensitive active agent. Formulations having an acid neutralization capacity of under 5.0 are also described as are methods of making particulate base coated acid and dosage forms using same.

Abstract: Described herein are preparations containing parathyroid hormone that has been stablized with an excipient and buffering agent. Preferred preparations incorporate human PTH(1-84), mannitol as excipient and citrate as buffering agent, and are incorporated in vials as a freeze-dried powder for reconstitution to treat osteoporosis.

Abstract: Disclosed is a semi-solid pharmaceutical agent containing a stabilized proteinaceous bioactive substance prepared by successively mixing an oligosaccharide and an aqueous solution of a proteinaceous bioactive substance, and kneading the resultant solids with an oil or fat base. The pharmaceutical handles with ease because it is readily administered to the body through percutaneous and permucosal route which are safer and less in pain administration routes than other conventional administrations.

Abstract: A process for reducing the content of free formaldehyde and formic acid in nonionic and anionic surfactants is provided. The process comprises adding an amine compound selected from the group consisting of a) alkanolamines, b) aminocarboxylic acids and c) oligopeptides to a surfactant comprised of a member selected from the group consisting of nonionic and anionic surfactants. The amine compound is preferably selected from the group consisting of a) an alkanolamine containing 2 to 15 carbon atoms, b) an aminocarboxylic acid containing 2 to 8 carbon atoms, and c) an oligopeptide with an average molecular weight of 500 to 5000. The nonionic and anionic surfactants preferably contain 1 to 100 ethylene oxide units in the form of at least one polyethylene glycol chain. The amine compound is preferably added in a quantity of 50 to 6000 ppm, based on active substance of said surfactant.

Abstract: The present invention provides an improved method of stabilizing of 3-isothiazolone solutions using bromate compounds by buffering the pH of the solution in the range of 4 to 5.1, and compositions which comprise 3-isothiazolone compound, bromate compound stabilizer, and sufficient buffer to maintain the pH in said range.

Abstract: Proteins having substantially the same biological activity as PDGF are provided. In one aspect, a protein homodimer having two polypeptide chains is disclosed, each of the chains being a mosaic of amino acid sequences substantially identical to portions of the A- and B-chains of PDGF, the protein being chemotactic or mitogenic for fibroblasts. Therapeutic compositions comprising such proteins in combination with a physiologically acceptable carrier or diluent are also provided. Such therapeutic compositions may be used within methods for enhancing the wound-healing process in warm-blooded animals.

Abstract: The present invention relates to aqueous depot formulations of hirudin, particularly desulphatohirudin, which are very stable. These formulations contain water, hirudin, and calcium, magnesium, or zinc ions in the form of water insoluble salts, the salts being in a concentration of from 100 mM to 600 mM.

Abstract: A biologically active composition made up of biodegradable core particles which are coated with a layer that is designed to allow attachment of biologically active agents without denaturing them. The composition may further include an exterior targeting membrane which provides selective targeting to specific receptors.

Abstract: A biologically active composition made up of core particles having diameters of less than about 1000 nanometers which are coated with a layer which is designed to allow attachment of biologically active proteins, peptides or pharmacological agents to the microparticles. When viral protein is attached to the core particles, the result is a viral decoy which accurately mimics the native virus in both size and structure while being entirely devoid of virulent activity due to the microparticle core. Other antigenic proteins or peptides are attached to provide molecules which are useful in raising antibodies or as a diagnostic tool. Further, pharmacological agents are attached to the microparticles to provide pharmaceutical compositions.

Abstract: A biologically active composition made up of core particles or surfaces which are coated with a layer which is designed to allow attachment of biochemically reactive pairs (BRP's) without denaturing the BRP to the microparticles. BRP's which may be attached include ligand-receptor pairs, enzyme-substrate pairs, drug-receptor pairs, catalyst-reactant pairs, toxin-ligand pairs, absorbant-absorbate pairs and adsorbant-adsorbate pairs.

Abstract: A biologically active composition for use in gene therapy and other transfection procedures. The composition is composed of nanocrystalline core particles which are coated with a layer that is designed to allow attachment of transfection agents (DNA/RNA segments or antisense fragments) without denaturing them. The composition may further include an exterior targeting membrane which provides selective targeting of the transfection agents to specific cell receptors.

Abstract: A controlled sustained release tablet having at least one year shelf life and containing bupropion hydrochloride, hydroxypropyl methylcellulose and cysteine hydrochloride or glycine hydrochloride with the tablet having a surface area to volume ratio to effectively control bupropion hydrochloride release in the body.

Abstract: Disclosed herein are compositions comprisinga) at least one 3-isothiazolone of the formula (I) ##STR1## wherein Y is an unsubstituted or substituted (C.sub.1 -C.sub.18) alkyl, an unsubstituted or substituted (C.sub.3 -C.sub.12) cycloalkyl, an unsubstituted or halogen-substituted (C.sub.2 -C.sub.8) alkenyl or alkynyl, an unsubstituted or substituted (C.sub.7 -C.sub.10) aralkyl, or an unsubstituted or substituted aryl; andR and R.sup.1 is each independently H, halogen or (C.sub.1 -C.sub.4) alkyl; andb) a carbonyl compound selected from the group consisting of (C.sub.2 -C.sub.6) aldehydes, (C.sub.7 -C.sub.10) aromatic aldehydes or acids, (C.sub.2 -C.sub.4) dialdehydes, (C.sub.1 -C.sub.12) acids, (C.sub.2 -C.sub.8) diacids, triacids or tetracids, (C.sub.3 -C.sub.10) .alpha.,.beta. unsaturated carbonyls, (C.sub.1 -C.sub.6) haloamides of the formula ##STR2## where R.sub.1 =phenyl or (C.sub.1 -C.sub.4)alkyl, substituted phenyl,R.sub.2 =(C.sub.1 -C.sub.7)alkyl, (C.sub.1 -C.sub.7)alkoxylalkyl, or (C.sub.1 -C.sub.

Abstract: Solid compositions of certain cholinergic compounds are stabilized in starch. Especially compositions of corn starch combined or mixed with the 0-substituted-1,2,5,6-tetrahydro-3-pyridine oxime ether, CI-979 HCl, a cognition activator, have been found stable in a heated environment of up to 60.degree. C. over 17 days such that no losses were detected by HPLC analysis. A solid peroral pharmaceutical formulation for the treatment of cognitive disorders is based on the bicomponent composition of active ingredient and stabilizer using appropriate amounts of other excipients or components known in the formulation art.

Abstract: The invention relates to fluid resuscitation of the human or animal body by administration of deferoxamine (DFO) and a water-soluble biopolymer.The DFO and the biopolymer are preferably bonded together.The biopolymer may be a polysaccharide or a protein.The DFO and the biopolymer are preferably formulated as an aqueous solution suitable for oral administration.The fluid resuscitation may be effected for ameliorating systemic oxidant injury occurring during ischemia and subsequent reperfusion.The fluid resuscitation may be indicated in treatment of burn injury, lung injury caused by inhalation of hot and/or toxic substances, such as smoke derived from combustion, hemorrhagic shock and other types of trauma.